Drugnews

What is a complete response letter?

A complete response letter means the FDA cannot approve an application in its current form. On November 15, 2026 (U.S. time), Summit Therapeutics announced that it had received this letter for Akeso’s ivonescimab. The 438-patient HARMONi trial’s primary overall survival p=0.057 missed the prespecified 0.0448 threshold; the decision concerns the submitted lung cancer indication.

Updated

Regulatory meaning and the ivonescimab case
MeasureReported resultBasis
General meaningApplication cannot be approved in its current formFDA explanation published July 10, 2025
DeficienciesSet out in the letterFDA may recommend steps to address them
Ivonescimab announcementNovember 15, 2026Summit company statement
Reported efficacy issueStatistically significant overall survival benefit not demonstratedSubmitted indication; not a decision on every potential use

Ivonescimab after the FDA letter

HARMONi reported median overall survival of 16.8 months with ivonescimab plus chemotherapy versus 14.0 months with chemotherapy. Subsequent first-line lung cancer evidence will come from HARMONi-3 and HARMONi-7.

November 17, 2026 analysis

Sources

Read the full analysis

FDA Rejects Akeso’s Bispecific: PFS Was Not Enough — November 17, 2026